Methocarbamol 1500mg tablets
Requires a prescription from a doctor or prescriber
Drugs used in neuromuscular disorders
Safety information for pregnancy and breastfeeding
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Methocarbamol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Methocarbamol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
5 branded products available
MHRA licensed products
View all licensed products for Methocarbamol on the MHRA register
Methocarbamol 1500mg tablets
Methocarbamol 1500mg tablets
Methocarbamol 1500mg tablets
Methocarbamol 1500mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
3 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Methocarbamol
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
1.14 hours
Mechanism
The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity.
Food interactions
2 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1.1 hours
[A636]…
Half-life
1.14 hours
Protein binding
46-50%
[A636]
Volume of distribution
515-942mL
[A178426]
Metabolism
[A178366]…
Elimination
88.85%
[A178366]…
Clearance
0.2-0.8L/h
[L6268]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.[Label,L6268] In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose that may be combined with [acetaminophen] or [ibuprofen].[L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295]
Methocarbamol was FDA approved on 16 July 1957.[L6265]
[A31312]
In Canada, methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm.
[L6295]
However, if these combination formulations include codeine, they are prescription only.
[L6295]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 670 interactions
The oral LD50 in rats is 3576.2mg/kg.
[L6295]
The FDA has classified methocarbamol as pregnancy category C.[Label] Animal and human studies have not been performed to determine the risks to a fetus, however fetal and congenital abnormalities have been reported.[Label] Methocarbamol is excreted in the milk of dogs, however it is unknown if this is also the case for humans.[Label] Caution should be exercised when taking methocarbamol while breastfeeding.[Label]
Studies to assess the carcinogenicity, mutagenicity, or effects on fertility of methocarbamol have not been performed.[Label]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A636]
The maximum plasma concentration is 21.3mg/L for healthy patients and 28.7mg/L in hemodialysis patients.
[A636]
The area under the curve for healthy patients is 52.5mg/L\*hr and 87.1mg/L*hr in hemodialysis patients.
[A636]
AUC% based on terminal elimination half life is 2% for healthy patients and 4% for hemodialysis patients.
[A636]
Older studies report maximum plasma concentrations in 0.5 hours.
[A178366]
[A636]
Older studies report half lives of 1.6-2.15 hours.
[A178366]
[A636]
[A178426]
[A178366]
Methocarbamol and its metabolites are conjugated through glucuronidation or sulfation.
[A178366]
[A178366]
In dogs, 88.85% of the dose is eliminated in urine and 2.14% in the feces.
[A178366]
In rats, 84.5-92.5% of the dose is eliminated in the urine and 0-13.3% is eliminated in the feces.
[A178366]
[L6268]
Proteins and enzymes this drug interacts with in the body
PMID:10550681 PMID:16506782 PMID:16686544 PMID:16807956 PMID:17127057 PMID:17314045 PMID:17407288 PMID:18618712 PMID:19186056 PMID:19206230
Can hydrate cyanamide to urea PMID:10550681
ATC M03BA73
ATC M03BA03
ATC M03BA53
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Methocarbamol
Additional database identifiers
Drugs Product Database (DPD)
6340
ChemSpider
3964
BindingDB
50239995
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1368
GenAtlas
CA1
GeneCards
CA1
GenBank Gene Database
X05014
GenBank Protein Database
29600
Guide to Pharmacology
2597
UniProt Accession
CAH1_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
1 active patent
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: